NCT04195958View on ClinicalTrials.gov

A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

PHASE4TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

October 18, 2021

Study Completion Date

October 18, 2021

Conditions
Moderate-to-severe Allergic Asthma
Interventions
DRUG

Omalizumab

Omalizumab will be administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency will be determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening.

Trial Locations (12)

10075

Lenox Hill Hospital, New York

19140

Temple Uni Medical Center; Pulmonary & Critical Care Medicine, Philadelphia

28277

American Health Research Inc., Charlotte

29303

Spartanburg Medical Research, Spartanburg

33024

Broward Research Center, Pembroke Pines

44016

University Hospitals Cleveland Medical Center, Cleveland

52242

University of Iowa Hospitals & Clinics; Internal Medicine, Iowa City

55905

Mayo Clinic - Rochester, Rochester

80206

National Jewish Health, Denver

90274

Peninsula Research Associates, Rolling Hills Estates

98122

Swedish Health Services, Seattle

48109-0934

University of Michigan, Ann Arbor

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT04195958 - A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma | Biotech Hunter | Biotech Hunter